Energy-Efficient Implementation of ECDH Key Exchange for Wireless Sensor Networks

Wireless Sensor Networks (WSNs) are playing a vital role in an ever-growing number of applications ranging from environmental surveillance over medical monitoring to home automation. Since WSNs are often deployed in unattended or even hostile environments, they can be subject to various malicious attacks, including the manipulation and capture of nodes. The establishment of a shared secret key between two or more individual nodes is one of the most important security services needed to guarantee the proper functioning of a sensor network. Despite some recent advances in this field, the efficient implementation of cryptographic key establishment for WSNs remains a challenge due to the resource constraints of small sensor nodes such as the MICAz mote. In this paper we present a lightweight implementation of the elliptic curve Diffie-Hellman (ECDH) key exchange for ZigBee-compliant sensor nodes equipped with an ATmega128 processor running the TinyOS operating system. Our implementation uses a 192-bit prime field specified by the NIST as underlying algebraic structure and requires only 5.20·10^6 clock cycles to compute a scalar multiplication if the base point is fixed and known a priori. A scalar multiplication using a random base point takes about 12.33·10^6 cycles. Our results show that a full ECDH key exchange between two MICAz motes consumes an energy of 57.33 mJ (including radio communication), which is significantly better than most previously reported ECDH implementations on comparable platforms

Animal production and canopy attributes of Cynodon pasture managed under continuous stocking with wethers at three levels of forage allowance

The objective of the present experiment was to evaluate the effect of forage allowance (3, 6 or 9 kg of green leaves dry matter (DM)/100 kg of body weight (BW)) on both animal performance and attributes of Cynodon dactylon var.dactylon canopy managed under continuous stocking by wethers. The study was carried out with 27 Polwarth wethers throughout five 28-day periods, in a completely randomized experiment, which included three paddocks per treatment and three tester animals per paddock. Forage mass varied from 2878 to 6580 kg of DM/ha and was directly related to forage allowance. Leaves proportion (mean of 23%) and leaves growth rate (mean of 25 kg of DM/ha/day) varied between experimental periods in a similar rate for all treatments. Stocking rate varied from 652 to 2428 kg of LW/ha/day and was higher for the lowest forage allowance treatment. Individual BW gain (mean of 9.7 g/day) or gain per area (mean of 406 g/ha/day) were only affected by experimental periods. Forage intake was neither affected by treatments nor by periods (mean of 1042 g of DM/day). Cynodon dactylon var. dactylon pasture may be managed under continuous stocking by grazing wethers at forage allowances varying from 3 to 9 kg of green leaves dry matter/100 kg of BW without effects on canopy attributes or animal production

Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective

Introduction Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature coronary artery disease, with significant potential for positive impact on public health and healthcare savings. New clinical practice recommendations are presented in an abridged guidance to assist practitioners in enhancing the care of all patients with FH. Main recommendations Core recommendations are made on the detection, diagnosis, assessment and management of adults, children and adolescents with FH. There is a key role for general practitioners (GPs) working in collaboration with specialists with expertise in lipidology. Advice is given on genetic and cholesterol testing and risk notification of biological relatives undergoing cascade testing for FH; all healthcare professionals should develop skills in genomic medicine. Management is under-pinned by the precepts of risk stratification, adherence to healthy lifestyles, treatment of non-cholesterol risk factors, and appropriate use of low-density lipoprotein (LDL)-cholesterol lowering therapies, including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Recommendations on service design are provided in the full guidance. Potential impact on care of FH These recommendations need to be utilised using judicious clinical judgement and shared decision making with patients and families. Models of care need to be adapted to both local and regional needs and resources. In Australia new government funded schemes for genetic testing and use of PCSK9 inhibitors, as well as the National Health Genomics Policy Framework, will enable adoption of these recommendations. A broad implementation science strategy is, however, required to ensure that the guidance translates into benefit for all families with FH

Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia

Familial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol concentration and, if untreated, leads to premature atherosclerosis and coronary artery disease (CAD). There are approximately 100,000 people with FH in Australia. However, an overwhelming majority of those affected remain undetected and inadequately treated, consistent with FH being a leading challenge for public health genomics. To further address the unmet need, we provide an updated guidance, presented as a series of systematically collated recommendations, on the care of patients and families with FH. These recommendations have been informed by an exponential growth in published works and new evidence over the last 5 years and are compatible with a contemporary global call to action on FH. Recommendations are given on the detection, diagnosis, assessment and management of FH in adults and children. Recommendations are also made on genetic testing and risk notification of biological relatives who should undergo cascade testing for FH. Guidance on management is based on the concepts of risk re-stratification, adherence to heart healthy lifestyles, treatment of non-cholesterol risk factors, and safe and appropriate use of LDL-cholesterol lowering therapies, including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein apheresis. Broad recommendations are also provided for the organisation and development of health care services. Recommendations on best practice need to be underpinned by good clinical judgment and shared decision making with patients and families. Models of care for FH need to be adapted to local and regional health care needs and available resources. A comprehensive and realistic implementation strategy, informed by further research, including assessments of cost-benefit, will be required to ensure that this new guidance benefits all Australian families with or at risk of FH

Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians

Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature coronary artery disease. New clinical practice recommendations are presented to assist practitioners in enhancing the care of all patients with FH. Core recommendations are made on the detection, diagnosis, assessment and management of adults, children and adolescents with FH. Management is under-pinned by the precepts of risk stratification, adherence to healthy lifestyles, treatment of non-cholesterol risk factors and appropriate use of low-density lipoprotein (LDL)-cholesterol-lowering therapies including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The recommendations need to be utilised using judicious clinical judgement and shared decision-making with patients and families. New government-funded schemes for genetic testing and use of PCSK9 inhibitors, as well as the National Health Genomics Policy Framework, will enable adoption of the recommendations. However, a comprehensive implementation science and practice strategy is required to ensure that the guidance translates into benefit for all families with FH